Zhenyu Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhenyu Yang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Lunxu Liu
Department of Thoracic Surgery and Institute of Thoracic Oncology West China Hospital, Sichuan University Chengdu China
4 shared publications - Chaowei Zou
Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
2 shared publications - Chenglin Guo
Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China
2 shared publications - Chengwu Liu
Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China
2 shared publications Dainan Zhang
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2 shared publications- Gao Zhang
Faculty of Dentistry, The University of Hong Kong
2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Scifiniti Publishing
- Vol. 3 (1)
Spatial Characteristics of the Immune Microenvironment in Brain Metastases Provide Critical Insights for Developing Predictive Markers for Anti-PD-1 Therapy
Brain metastases (BrM) exhibit variable intracranial responses to immune checkpoint blockade (ICB), and reliable biomarkers of benefit remain uncertain, possibly reflecting the distinctive brain microenvironment. This review discusses multiplex protein imaging, array-based spatial transcriptomics, and in situ RNA imaging as complementary approaches for studying BrM and summarizes findings on regional differences in immune access and tumor cell states, CD8+ T cell localization and tumor contact, macrophage-associated and perivascular niches, tertiary lymphoid structure (TLS) signatures and organization, and potentially tumor-reactive or progenitor-like exhausted T cell populations. The clinical significance of these features varies. TLS signatures and several immune cell measures have been associated with survival, whereas differences in T cell infiltration and perivascular macrophage organization have been reported between ICB-treated and ICB-naive BrM specimens. However, most studies are retrospective, rely on selected surgical specimens, and establish prognostic or treatment-associated relationships rather than prospectively validated predictors of anti-PD-1/PD-L1 benefit. Finally, the review considers how targeted, reproducible spatial measures could be benchmarked with conventional biomarkers and validated in prospective, tumor-type-specific intracranial cohorts before clinical use.
- 27 October 2026
- Published by Scifiniti Publishing
- Vol. 3 (1)
Open AccessSpatial Characteristics of the Immune Microenvironment in Brain Metastases Provide Critical Insights for Developing Predictive Markers for Anti-PD-1 Therapy
Brain metastases (BrM) exhibit variable intracranial responses to immune checkpoint blockade (ICB), and reliable biomarkers of benefit remain uncertain, possibly reflecting the distinctive brain microenvironment. This review discusses multiplex protein imaging, array-based spatial transcriptomics, and in situ RNA imaging as complementary approaches for studying BrM and summarizes findings on regional differences in immune access and tumor cell states, CD8+ T cell localization and tumor contact, macrophage-associated and perivascular niches, tertiary lymphoid structure (TLS) signatures and organization, and potentially tumor-reactive or progenitor-like exhausted T cell populations. The clinical significance of these features varies. TLS signatures and several immune cell measures have been associated with survival, whereas differences in T cell infiltration and perivascular macrophage organization have been reported between ICB-treated and ICB-naive BrM specimens. However, most studies are retrospective, rely on selected surgical specimens, and establish prognostic or treatment-associated relationships rather than prospectively validated predictors of anti-PD-1/PD-L1 benefit. Finally, the review considers how targeted, reproducible spatial measures could be benchmarked with conventional biomarkers and validated in prospective, tumor-type-specific intracranial cohorts before clinical use.
- Open Access
- 8 July 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Spotlight on challenges and novel methods in highly multiplexed tissue imaging-based spatial proteomics
Tissue microenvironment heterogeneity, including cellular composition, functional states, and intercellular interactions, shapes complex biological process
- 8 July 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessSpotlight on challenges and novel methods in highly multiplexed tissue imaging-based spatial proteomics
Tissue microenvironment heterogeneity, including cellular composition, functional states, and intercellular interactions, shapes complex biological process
- Open Access
- 15 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Author Correction: A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities
- 15 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAuthor Correction: A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities
- Open Access
- 26 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities
The molecular heterogeneity of brain metastases hampers therapeutic development for cures. To address this unmet and urgent need, we construct a comprehensive multi-omic, single cell, and spatially resolved atlas of 1,032 pan-cancer brain metastases, identifying four robust molecular subtypes with distinct biological programs and clinical associations. These brain metastases subtypes (BrMS) are defined by unique biological states: neural-like (BrMS1), metabolic (BrMS3), highly proliferative/immune-excluded (BrMS4), and an immune-infiltrated (BrMS2) state featuring a coordinated epithelial-mesenchymal transition program. Patient-derived organoids coupled with targeted drug screening indicate subtype-specific molecular dependencies and putative targets, notably mTOR signaling activation in BrMS3 and CDK4/6 axis activation in BrMS4, while BrMS1 and BrMS2 display distinct radiobiologic and immunologic signatures. This atlas provides a rigorous classification framework of BrMs and offers insights into subtype-specific molecular vulnerabilities.
- 26 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities
The molecular heterogeneity of brain metastases hampers therapeutic development for cures. To address this unmet and urgent need, we construct a comprehensive multi-omic, single cell, and spatially resolved atlas of 1,032 pan-cancer brain metastases, identifying four robust molecular subtypes with distinct biological programs and clinical associations. These brain metastases subtypes (BrMS) are defined by unique biological states: neural-like (BrMS1), metabolic (BrMS3), highly proliferative/immune-excluded (BrMS4), and an immune-infiltrated (BrMS2) state featuring a coordinated epithelial-mesenchymal transition program. Patient-derived organoids coupled with targeted drug screening indicate subtype-specific molecular dependencies and putative targets, notably mTOR signaling activation in BrMS3 and CDK4/6 axis activation in BrMS4, while BrMS1 and BrMS2 display distinct radiobiologic and immunologic signatures. This atlas provides a rigorous classification framework of BrMs and offers insights into subtype-specific molecular vulnerabilities.
- Open Access
- 24 June 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (12) , 7871-7879
The prognostic value of visceral pleural infiltration in ≤3 cm nonsmall cell lung cancer presenting with ground glass opacity: an inverse probability of treatment weighting study
Background: Visceral pleural infiltration (VPI) has been identified as an important risk factor in nonsmall cell lung cancer (NSCLC) for many decades. However, for patients who present with ground glass opacity (GGO), the prognostic value of VPI is still elusive. The authors aimed to investigate whether the VPI is a significant prognostic factor in surgically resected ≤3 cm stage I NSCLC, who presented with GGO. Materials and methods: Patients with primary NSCLC who underwent surgical resection between December 2009 and December 2018 were collected. Stage I tumors that presented as GGO nodules with a tumor size of less than 3 cm were included and divided into two groups based on VPI status (positive and negative). Clinical, pathological, and prognostic data were prospectively collected and retrospectively reviewed. Inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using the Cox proportional hazards model and Kaplan–Meier method. Results: A total of 2043 patients were included in this study (VPIs were found in 196 patients). After IPTW weighting, all factors between the two groups were balanced. The median follow-up time was 67.3 months. According to the multivariable Cox models, the VPI was not a significant prognostic factor for OS (HR=2.00, 95% CI: 0.96–4.17; P=0.063), but was significant for RFS (HR=2.00, 95% CI: 1.12–3.55; P=0.019). In subgroup analysis, we found VPI was significant for OS (HR=3.17, 95% CI: 1.09–9.26, P=0.035) and RFS (HR=4.07, 95% CI: 1.76–9.40, P=0.001) in patients with a tumor size >1 cm and a consolidation to tumor ratio (CTR) >50%. For patients with a tumor size ≤1 cm or a CTR ≤50%, the VPI was not significant. Conclusions: VPI may be a significant risk factor for GGOs in NSCLC patients with a tumor size >1 cm and a CTR >50%. Further prospective studies conducted across multicenters with a larger sample size are needed.
- 24 June 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (12) , 7871-7879
Open AccessThe prognostic value of visceral pleural infiltration in ≤3 cm nonsmall cell lung cancer presenting with ground glass opacity: an inverse probability of treatment weighting study
Background: Visceral pleural infiltration (VPI) has been identified as an important risk factor in nonsmall cell lung cancer (NSCLC) for many decades. However, for patients who present with ground glass opacity (GGO), the prognostic value of VPI is still elusive. The authors aimed to investigate whether the VPI is a significant prognostic factor in surgically resected ≤3 cm stage I NSCLC, who presented with GGO. Materials and methods: Patients with primary NSCLC who underwent surgical resection between December 2009 and December 2018 were collected. Stage I tumors that presented as GGO nodules with a tumor size of less than 3 cm were included and divided into two groups based on VPI status (positive and negative). Clinical, pathological, and prognostic data were prospectively collected and retrospectively reviewed. Inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using the Cox proportional hazards model and Kaplan–Meier method. Results: A total of 2043 patients were included in this study (VPIs were found in 196 patients). After IPTW weighting, all factors between the two groups were balanced. The median follow-up time was 67.3 months. According to the multivariable Cox models, the VPI was not a significant prognostic factor for OS (HR=2.00, 95% CI: 0.96–4.17; P=0.063), but was significant for RFS (HR=2.00, 95% CI: 1.12–3.55; P=0.019). In subgroup analysis, we found VPI was significant for OS (HR=3.17, 95% CI: 1.09–9.26, P=0.035) and RFS (HR=4.07, 95% CI: 1.76–9.40, P=0.001) in patients with a tumor size >1 cm and a consolidation to tumor ratio (CTR) >50%. For patients with a tumor size ≤1 cm or a CTR ≤50%, the VPI was not significant. Conclusions: VPI may be a significant risk factor for GGOs in NSCLC patients with a tumor size >1 cm and a CTR >50%. Further prospective studies conducted across multicenters with a larger sample size are needed.
- Open Access
- 21 March 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (7) , 4231-4239
Intentional wedge resection versus segmentectomy for ≤2 cm ground-glass-opacity-dominant non-small cell lung cancer: a real-world study using inverse probability of treatment weighting
Background: Whether wedge resection is oncological suitable for ground glass opacity (GGO)-dominant non-small cell lung cancer (NSCLC) ≤2 cm is still debatable. The aim of this study is to investigate the short-term and long-term outcomes of intentional wedge resection and segmentectomy for those patients. Materials and Methods: This was a real-world study from one of the largest thoracic surgery centers in West China. Patients who underwent intentional wedge resection or segmentectomy for ≤2 cm CTR (consolidation-to-tumor) ≤0.5 NSCLC were consecutively included between December 2009 and December 2018. Data were prospectively collected and retrospectively reviewed. Inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics. Long-term outcomes, including overall survival (OS), recurrence-free survival (RFS), and lung cancer-specific survival (LCSS), were analyzed using Cox proportional model. Results: A total of 1209 patients were included (497 in the wedge resection group, 712 in the segmentectomy group). Compared to segmentectomy, wedge resection had a significantly lower rate of complications (3.8 vs. 7.7%, P=0.008), a shorter operating time (65 min vs. 114 min, PPP=0.270), 5-year RFS (98.8 vs. 99.5%, HR=1.88, 95% CI: 0.56–6.31, P=0.307) and 5-year LCSS (99.9 vs. 99.6%, HR=1.76, 95% CI: 0.24–13.15, P=0.581). Conclusion: Intentional wedge resection is an appropriate choice for ≤2 cm GGO-dominant NSCLC.
- 21 March 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (7) , 4231-4239
Open AccessIntentional wedge resection versus segmentectomy for ≤2 cm ground-glass-opacity-dominant non-small cell lung cancer: a real-world study using inverse probability of treatment weighting
Background: Whether wedge resection is oncological suitable for ground glass opacity (GGO)-dominant non-small cell lung cancer (NSCLC) ≤2 cm is still debatable. The aim of this study is to investigate the short-term and long-term outcomes of intentional wedge resection and segmentectomy for those patients. Materials and Methods: This was a real-world study from one of the largest thoracic surgery centers in West China. Patients who underwent intentional wedge resection or segmentectomy for ≤2 cm CTR (consolidation-to-tumor) ≤0.5 NSCLC were consecutively included between December 2009 and December 2018. Data were prospectively collected and retrospectively reviewed. Inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics. Long-term outcomes, including overall survival (OS), recurrence-free survival (RFS), and lung cancer-specific survival (LCSS), were analyzed using Cox proportional model. Results: A total of 1209 patients were included (497 in the wedge resection group, 712 in the segmentectomy group). Compared to segmentectomy, wedge resection had a significantly lower rate of complications (3.8 vs. 7.7%, P=0.008), a shorter operating time (65 min vs. 114 min, PPP=0.270), 5-year RFS (98.8 vs. 99.5%, HR=1.88, 95% CI: 0.56–6.31, P=0.307) and 5-year LCSS (99.9 vs. 99.6%, HR=1.76, 95% CI: 0.24–13.15, P=0.581). Conclusion: Intentional wedge resection is an appropriate choice for ≤2 cm GGO-dominant NSCLC.